Rubraca
Pharma&’s ovarian cancer therapy approved for use by NHS Scotland
October 29, 2025Pharma&, Rubraca, Scottish Medicines Consortium, nhs scotland, oncology, ovarian cancer
Pharma& has announced that its treatment for ovarian cancer, Rubraca (rucaparib), has been accepted by the Scottish Medicines Consortium (SMC) …
Clovis Oncology’s Rubraca now available via the Cancer Drugs Fund for ovarian, peritoneal, fallopian tube cancer
October 11, 2019Medical Communications, Sales and Marketing Cancer, Clovis Oncology, NHS, NICE, Rubraca, fallopian tube cancer, ovarian cancer, peritoneal cancer, pharma
NICE has announced it has made an about-face on its earlier ruling for Clovis Oncology’s Rubraca (rucaparib), revealing that the …
NICE reject Clovis Oncology’s ovarian cancer drug Rubraca
August 6, 2019Manufacturing and Production NHS, NICE, Rubraca, UK, guidance, pharma
Britain’s cost-effectiveness body NICE has chosen not to recommend Clovis Oncology’s cancer drug Rubraca (rucaparib). On 6 August, NICE issued …
Clovis Oncology’s Rubraca shows promise in multiple pancreatic tumour mutations, interim data show
April 3, 2019Research and Development Cancer, Clovis Oncology, Pancreatic cancer, Rubraca, oncology, pharma
At the 2019 American Association for Cancer Research (AACR) Annual Meeting in Atlanta, Clovis Oncology took the opportunity to present …
Latest content
Scots neonatal innovations target hearing loss and earlier care
August 28, 2026
Agentis Health Group acquires Clinical Pharmacist Solutions
August 26, 2026
